Department of Mechanical and Aerospace Engineering, New York University, Brooklyn, NY 11201, USA; Department of Biomedical Engineering, New York University, Brooklyn, NY 11201, USA.
Department of Biomedical Engineering, New York University, Brooklyn, NY 11201, USA.
Trends Pharmacol Sci. 2021 Feb;42(2):119-133. doi: 10.1016/j.tips.2020.11.009. Epub 2020 Dec 16.
The pharmaceutical industry has been desperately searching for efficient drug discovery methods. Organ-on-a-Chip, a cutting-edge technology that can emulate the physiological environment and functionality of human organs on a chip for disease modeling and drug testing, shows great potential for revolutionizing the drug development pipeline. However, successful translation of this novel engineering platform into routine pharmacological and medical scenarios remains to be realized. In this review, we discuss how the Organ-on-a-Chip technology can have critical roles in different preclinical stages of drug development and highlight the current challenges in translation and commercialization of this technology for the pharmacological and medical end-users. Moreover, this review sheds light on the future developmental trends and need for a next-generation Organ-on-a-Chip platform to bridge the gap between animal studies and clinical trials for the pharmaceutical industry.
制药行业一直在拼命寻找高效的药物发现方法。器官芯片是一种前沿技术,可以在芯片上模拟人体器官的生理环境和功能,用于疾病建模和药物测试,为药物开发管道的变革带来了巨大的潜力。然而,要将这个新颖的工程平台成功转化为常规的药理学和医学应用场景,仍有待实现。在这篇综述中,我们讨论了器官芯片技术如何在药物开发的不同临床前阶段发挥关键作用,并强调了该技术在药理学和医学终端用户中的转化和商业化所面临的当前挑战。此外,本文还探讨了未来的发展趋势以及对下一代器官芯片平台的需求,以缩小动物研究和临床试验之间的差距,为制药行业服务。